Ticker brief
CRSP CRISPR THERAPEUTICS AG
Consumer, Non-cyclical · Biotechnology
last close
$49.39
1 day
-1.2%
14 days
-7.5%
mkt cap
$5.9B
signals 14d
25
authors 14d
13
crowd 14d
+0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 63% mid · 51 pctile own 1y | IV/HV 1.07× (as of 2026-10-16) |
| Skew — 25Δ RR 30d | +0.033 69 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.35 thin | 5-session Δ -0.87 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2025-07-22 (z=2.4) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-15 · now +0.05 (−1 bearish … +1 bullish)
Who spoke13
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @MisterInversor | C | -5.25 | 9 | +0.53 |
| @DustinHuntwn | C | -3.75 | 3 | +0.53 |
| @mark_to_mkt | C | -0.67 | 2 | +0.10 |
| @MMMTwealth | A | -0.39 | 2 | +0.48 |
| @nanalyzetweets | B | +5.59 | 1 | +0.20 |
| @AlexsOptions | C | -1.18 | 1 | -0.30 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @Gobbb111 | C | -0.71 | 1 | +0.70 |
| @SeegerErik | C | -1.23 | 1 | +0.00 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @TalkMarkets | C | · | 1 | +0.30 |
| @cnfinancewatch | B | -1.23 | 1 | +0.45 |
| @OracleNYSE | C | +0.83 | 1 | +0.20 |
Recent signals25of 25 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @DustinHuntwn | +0.05 | Bare promotional biotech list with no explicit trade action or thesis. | -4.1% | tweet ↗ |
| 2026-10-14 | @OracleNYSE | +0.20 | FDA launched a rare-disease review overhaul seeking flexible approvals for small populations. | -1.7% | tweet ↗ |
| 2026-10-14 | @MisterInversor | +0.50 | Links worsening population health to a bullish long-term healthcare innovation basket. | -1.7% | tweet ↗ |
| 2026-10-12 | @MisterInversor | +0.45 | Presents six names as beneficiaries of an accelerating biotech and health revolution. | -4.2% | tweet ↗ |
| 2026-10-12 | @cnfinancewatch | +0.45 | Maps four listed gene-editing companies to distinct technology platforms and leadership claims. | -4.2% | tweet ↗ |
| 2026-10-11 | @TalkMarkets | +0.30 | Reports Cathie Wood selling DraftKings and buying CRISPR Therapeutics; remaining cashtags are incidental. | -7.5% | tweet ↗ |
| 2026-10-11 | @MisterInversor | +0.55 | Frames AI plus biology as a historic revolution and presents six companies as beneficiaries. | -7.5% | tweet ↗ |
| 2026-10-10 | @DustinHuntwn | +0.80 | Presents a fundamentals-backed basket of biotech stocks with claimed 10x potential; capped at six. | -7.5% | tweet ↗ |
| 2026-10-09 | @DustinHuntwn | +0.75 | Presents six biotech and health-tech stocks as potential tenfold winners with operating metrics. | -7.5% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.00 | CRISPR Therapeutics scheduled Phase 1 hypertriglyceridemia results for CTX-310 on Nov. 9. | -7.5% | tweet ↗ |
| 2026-10-09 | @MisterInversor | +0.25 | Reports strong daily gains across the author's biotech holdings. | -7.5% | tweet ↗ |
| 2026-10-09 | @MMMTwealth | +0.55 | Presents a multi-sector basket spanning AI biology, crypto, commodities, optics and power. | -7.5% | tweet ↗ |
| 2026-10-09 | @SeegerErik | +0.00 | Reports QSI's 19-amino-acid Proteus milestone and price gain; peers appear only in an analyst headline | -7.5% | tweet ↗ |
| 2026-10-09 | @Gobbb111 | +0.70 | Presents six biotech stocks as potential 10x plays with operating and revenue evidence. | -7.5% | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.00 | Biotech news roundup reports concrete clinical, regulatory and corporate events. | -2.1% | tweet ↗ |
| 2026-10-08 | @MMMTwealth | +0.40 | Watchlist identifies four high-beta names at interesting levels with brief theses. | -2.1% | tweet ↗ |
| 2026-10-08 | @MisterInversor | +0.45 | Says CRSP continues making forward progress. | -2.1% | tweet ↗ |
| 2026-10-07 | @MisterInversor | +0.50 | Bullish multi-year theme on accelerating big-tech investment in biotech and healthcare. | -5.7% | tweet ↗ |
| 2026-10-06 | @AlexsOptions | -0.30 | Cites simultaneous technical breaks across biotechnology names as evidence. | -8.5% | tweet ↗ |
| 2026-10-06 | @mark_to_mkt | -0.20 | Attributes biotech weakness to momentum-fund deleveraging and hopes the sector can consolidate. | -8.5% | tweet ↗ |
| 2026-10-06 | @mark_to_mkt | +0.40 | Notes CRSP is up premarket and may be breaking above a consolidation box. | -8.5% | tweet ↗ |
| 2026-10-05 | @MisterInversor | +0.65 | Predicts multiple biotech and health multibaggers over the next two to five years. | -13.9% | tweet ↗ |
| 2026-10-04 | @MisterInversor | +0.70 | Names CRISPR Therapeutics as the most likely leading winner in gene editing. | -10.9% | tweet ↗ |
| 2026-10-03 | @MisterInversor | +0.75 | Author expects a six-stock biotechnology and health basket to strongly outperform over five years. | -10.9% | tweet ↗ |
| 2026-10-03 | @nanalyzetweets | +0.20 | Presents genomics stocks to consider across genetic testing and gene-editing categories. | -10.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.